Sino Biopharmaceutical Limited
Sino Biopharmaceutical Limited (SBMFF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Sino Biopharmaceutical Limited (SBMFF), featuring income statements, balance sheets, and cash flow data.
Sino Biopharmaceutical Limited (SBMFF) Income Statement & Financial Overview
Explore comprehensive income reports for Sino Biopharmaceutical Limited SBMFF, broken down by year and quarter.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $6.50B | $6.50B | $7.94B | $7.94B |
| Cost of Revenue | $1.25B | $1.25B | $1.42B | $1.42B |
| Gross Profit | $5.25B | $5.25B | $6.51B | $6.51B |
| Gross Profit Ratio | $0.81 | $0.81 | $0.82 | $0.82 |
| R&D Expenses | $1.26B | $1.26B | $1.29B | $1.29B |
| SG&A Expenses | $2.66B | $2.66B | $3.42B | $3.42B |
| Operating Expenses | $3.91B | $3.91B | $4.71B | $4.71B |
| Total Costs & Expenses | $5.16B | $5.16B | $6.14B | $6.14B |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $234.96M | $240.60M | $240.60M | $240.60M |
| EBITDA | $1.08B | $1.09B | $1.98B | $1.98B |
| EBITDA Ratio | $0.17 | $0.17 | $0.25 | $0.25 |
| Operating Income | $1.34B | $1.34B | $1.80B | $1.80B |
| Operating Income Ratio | $0.21 | $0.21 | $0.23 | $0.23 |
| Other Income/Expenses (Net) | -$507.24M | -$507.24M | $5.34M | $5.34M |
| Income Before Tax | $831.73M | $831.73M | $1.81B | $1.81B |
| Income Before Tax Ratio | $0.13 | $0.13 | $0.23 | $0.23 |
| Income Tax Expense | $60.59M | $60.59M | $307.05M | $307.05M |
| Net Income | $241.34M | $241.34M | $1.51B | $1.51B |
| Net Income Ratio | $0.04 | $0.04 | $0.19 | $0.19 |
| EPS | $0.01 | $0.01 | $0.02 | $0.04 |
| Diluted EPS | $0.01 | $0.01 | $0.04 | $0.04 |
| Weighted Avg Shares Outstanding | $17.24B | $17.24B | $39.39B | $39.39B |
| Weighted Avg Shares Outstanding (Diluted) | $18.18B | $18.18B | $18.41B | $39.39B |
Over the past four quarters, Sino Biopharmaceutical Limited demonstrated steady revenue growth, increasing from $7.94B in Q1 2024 to $6.50B in Q4 2024. Operating income reached $1.34B in Q4 2024, maintaining a consistent 21% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $1.08B, reflecting operational efficiency. Net income rose to $241.34M, with EPS at $0.01. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan